文献速递肿瘤 PET/CT核素与放射性配体治疗

RECIP 1.0可预测转移性去势抵抗性前列腺癌患者接受[177Lu]Lu-PSMA放射性药物治疗后的无进展生存期

RECIP 1.0 Predicts Progression-Free Survival After [177Lu]Lu-PSMA Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer.
PubMed 文献 · J Nucl Med · 2024-06-03

这项多中心回顾性研究纳入124例接受[177Lu]Lu-PSMA放射性药物治疗的转移性去势抵抗性前列腺癌患者,在基线和12周时行PSMA PET/CT并按RECIP 1.0评估。视觉RECIP 1.0评估为进展期病变的患者,其前列腺特异性抗原无进展生存期显著短于疾病稳定或部分缓解患者。

要点

  • 124例患者中,RECIP 1.0评估为完全缓解、部分缓解、疾病稳定和进展期病变者分别占0%、23%、44%和33%。
  • RECIP 1.0评估为进展期病变患者的PSA-PFS为2.6个月,短于疾病稳定者的6.4个月和部分缓解者的8.4个月(P < 0.001)。
  • RECIP 1.0评估为进展期病变者 vs 非进展期病变者的中位PSA-PFS为2.6 vs 7.2个月(HR 13.0;95%CI 7.0-24.1;P < 0.001)。

核心结论

  • 在[177Lu]Lu-PSMA治疗2个周期后行PSMA PET/CT并按RECIP 1.0评估,对PSA-PFS具有预后价值。
  • 作者认为RECIP 1.0 PSMA PET/CT可用于前列腺癌更早期阶段评估药物疗效并预测无进展生存期。

研究设计与样本

  • 多中心回顾性研究,纳入在3家学术中心接受[177Lu]Lu-PSMA放射性药物治疗的转移性去势抵抗性前列腺癌患者。
  • 287例筛查患者中124例符合纳入标准,均在基线和12周时接受PSMA PET/CT。
  • PSMA PET/CT图像对由5名阅片者按视觉RECIP 1.0评估。
  • 主要结局为RECIP与前列腺特异性抗原无进展生存期(PSA-PFS)的关联,采用Kaplan-Meier分析。

主要发现

  • 124例患者中,视觉RECIP 1.0评估为完全缓解、部分缓解、疾病稳定、进展期病变者分别为0例(0%)、29例(23%)、54例(44%)、41例(33%)。
  • 视觉RECIP 1.0评估为进展期病变者的PSA-PFS显著短于疾病稳定者与部分缓解者(2.6 vs 6.4 vs 8.4个月;P < 0.001)。
  • RECIP 1.0评估为进展期病变者 vs 非进展期病变者的中位PSA-PFS为2.6 vs 7.2个月(HR 13.0;95%CI 7.0-24.1;P < 0.001)。

关键数值与推荐

  • RECIP 1.0为基于循证的前列腺特异性膜抗原(PSMA)PET/CT疗效评估框架。
  • RECIP 1.0评估为进展期病变者 vs 非进展期病变者的中位PSA-PFS为2.6 vs 7.2个月(HR 13.0;95%CI 7.0-24.1;P < 0.001)。

临床怎么用

  • 原文结论认为,[177Lu]Lu-PSMA治疗2个周期后行PSMA PET/CT并按RECIP 1.0评估,对PSA-PFS具有预后价值。
  • 作者认为RECIP 1.0 PSMA PET/CT可用于前列腺癌更早期阶段评估药物疗效并预测无进展生存期。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Response Evaluation Criteria in Prostate-Specific Membrane Antigen Imaging (RECIP) 1.0 is an evidence-based framework to evaluate therapeutic efficacy in metastatic prostate cancer using prostate-specific membrane antigen (PSMA) PET/CT. This study aimed to evaluate the associations of interim PSMA PET/CT by RECIP 1.0 with short-term outcome after radiopharmaceutical treatment. Methods: This multicenter retrospective study included patients with metastatic castration-resistant prostate cancer who underwent [177Lu]Lu-PSMA radiopharmaceutical therapy at 3 academic centers and received PSMA PET/CT at baseline and at 12 wk. Pairs of PSMA PET/CT images were assessed by 5 readers for visual RECIP 1.0. The primary outcome was the association of RECIP with prostate-specific antigen progression-free survival (PSA-PFS) by Kaplan-Meier analysis. Results: In total, 124 of 287 screened patients met the inclusion criteria, with 0 (0%), 29 (23%), 54 (44%), and 41 (33%) of those 124 patients having complete response, partial response, stable disease, or progressive disease (PD) by visual RECIP 1.0, respectively. Patients with visual RECIP PD had a significantly shorter PSA-PFS than those with RECIP stable disease or with RECIP partial response (2.6 vs. 6.4 vs. 8.4 mo; P < 0.001). The median PSA-PFS among patients with RECIP PD versus those with non-RECIP PD was 2.6 versus 7.2 mo (hazard ratio, 13.0; 95% CI, 7.0-24.1; P < 0.001). Conclusion: PSMA PET/CT by RECIP 1.0 after 2 cycles of [177Lu]Lu-PSMA is prognostic for PSA-PFS. PSMA PET/CT by RECIP 1.0 may be used in earlier stages of prostate cancer to evaluate drug efficacy and to predict progression-free survival.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Gafita A, Djaileb L, Rauscher I, et al. RECIP 1.0 Predicts Progression-Free Survival After [177Lu]Lu-PSMA Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer. J Nucl Med. 2024. PMID: 38637143. doi:10.2967/jnumed.123.267234

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。